Official international sources
WHO AFRO Weekly External Situation Report 15
The latest WHO AFRO weekly aggregate found, with DRC data as of 23 August: 5,584 confirmed cases and 2,680 confirmed deaths. It reports 563 additional cases and 302 deaths versus report 14. WHO describes sustained transmission, high mortality and continuing geographic expansion, with persistent transmission in Ituri hotspots and intensifying transmission in parts of North Kivu and Haut-Uele.
WHO AFRO: 100 days since outbreak declaration
The 24 August statement calls this the fastest-growing Ebola outbreak in DRC history, reports about 90 confirmed cases per day during the first three months and warns that transmission is outpacing control efforts. This is a trend and operational assessment; the numerical status comes from newer SitRep 102.
DRC INSP / COUSP SitRep 102
The latest primary national status: data as of 24 August, with the document and website giving a 25 August publication date. It reports 5,656 confirmed cases, 2,715 confirmed deaths, 1,245 recoveries, 792 patients in isolation or treatment centres, 80.9% of contacts under follow-up and 58 affected health zones in six provinces. It directly reports 72 cases and 35 deaths for 24 August; Ganga in Bas-Uele is newly affected.
DRC INSP / COUSP SitReps 100–101
Primary daily sources preceding SitRep 102: 100 with data as of 22 August and 101 with data as of 23 August. SitRep 101 directly reports 70 cases and 38 deaths, 1,215 recoveries, 846 patients in isolation or treatment centres and 83.4% of contacts under follow-up. Values are not reconstructed from cumulative differences.
DRC INSP / COUSP SitReps 86–92
Primary daily sources for seven older chart points; SitRep 93 is listed separately in the detailed inventory below: 86, 87, 88, 89, 90, 91 and 92. Daily cases and deaths are transcribed directly; differences between cumulative totals do not replace reported daily values when corrections and harmonisation occur.
DRC INSP / COUSP SitRep 90: Bas-Uele
Primary confirmation of the sixth affected province, with data as of 12 August: one confirmed case and one confirmed death in the Buta health zone. SitRep 93 still retained this status; SitRep 96 subsequently confirmed a second case in newly affected Viadana health zone.
WHO Alert and response: daily update 20260824
At the 26 August check, the country rows list the DRC at 5,514 confirmed cases, 2,642 deaths and 1,200 recoveries as of 22 August, Uganda at 20/2/18 as of 21 July and France at 1/0/1 as of 6 July. The Total row agrees with the country sum: 5,535 confirmed cases, 2,644 confirmed deaths and 1,219 recoveries. The countries nevertheless have different cut-off dates.
WHO rapid risk assessment, version 4
The assessment published on 20 August, with risk characterised as of 14 August, classifies risk as very high in the DRC, high in countries sharing a land border with the DRC, and low in the rest of Africa and globally. It is used for the risk framework, not for newer national counts.
WHO / Africa CDC: vaccine allocation to the DRC
On 20 August they announced an immediate initial allocation of 70,000 Ervebo doses: 20,000 for a Phase III trial and 50,000 for health and frontline workers. Protection against BDBV in humans is unproven; WHO says it is essential that recipients receive information about risks, possible benefits and limitations and can give informed consent.
WHO Director-General's opening remarks at the second IHR Emergency Committee meeting
The meeting was held on 18 August. The WHO Director-General said the outbreak was far from under control and the risk of further national and international spread remained high. He also confirmed that two vaccines designed specifically for BDBV had entered human trials and that the PARTNERS treatment trial had enrolled 100 patients. The opening remarks are not the meeting outcome, evidence of efficacy or an approval.
WHO: second IHR Emergency Committee meeting and updated temporary recommendations
WHO published the recommendations on 24 August after the 18 August meeting. For the DRC, they now also address social measures, mass gatherings and domestic mobility. Other states are advised on readiness and traveller information, including discouraging travel to areas with community transmission; WHO does not recommend flight suspensions or denial of entry to travellers. The event remains a PHEIC.
ECDC outbreak page, updated 24 August
ECDC reports 5,514 confirmed cases, 2,642 confirmed deaths, 808 patients in isolation or treatment centres, follow-up of 83.4% of listed contacts and 57 of 151 affected health zones in six provinces in the DRC as of 22 August. It continues to assess the likelihood of infection for people living in the EU/EEA as very low.
Pletschette and Biedenkopf, npj Vaccines
The peer-reviewed comment, version of record dated 22 August, reviews BDBV vaccine-candidate preparedness and longer-term lessons. It is expert context, not a new clinical-trial result, evidence of efficacy or a change in regulatory status.
WHO: protecting health care and maintaining essential services
Operational guidance dated 17 August on protecting health services and maintaining essential care in eastern DRC. It is used as response context, not as a new epidemiological count.
Li et al., medRxiv, 18 August 2026
A non-peer-reviewed modelling preprint using public aggregate data through 11 August. It is retained as expert context; its older cut-off and preprint status mean it does not replace primary counts or current recommendations.
WHO AFRO: cross-border consultation in Bangui
The 14 August report describes a consultation involving the Central African Republic, the DRC, the Republic of the Congo, South Sudan and Uganda, preparation of a joint roadmap and a mobile laboratory in Obo. This is regional preparedness and border surveillance, not a new confirmed case in the Central African Republic.
WHO Alert and response: previous daily update 20260810
The previous synchronised WHO overview checked on 11 August reported 4,230 confirmed cases, 1,918 confirmed deaths, 1 probable case, 1 probable death and 847 recovered. The total matched the country rows for the DRC 4,209 as of 7 August, Uganda 20 as of 21 July and France 1 as of 6 July.
Associated Press: precautionary action involving a vessel at Maluku
On 9 August, AP reported, citing the DRC Ministry of Health and INRB, that more than 200 passengers had been temporarily held near Maluku and screened; all suspected cases that were tested were negative. The event therefore does not represent a confirmed case in Kinshasa and remains explicitly attributed to the media report.
WHO AFRO Weekly External Situation Report 12
The weekly report with data as of 2 August describes the event as the largest recorded BDBV outbreak and the second-largest Ebola outbreak in history after West Africa 2013–2016. WHO reports exceptional growth, an expansion phase and a high risk of regional and international spread, while stating that no new international spread had been detected. The report does not establish a mutation changing transmissibility or severity.
WHO AFRO: diagnosis closer to border communities
The 4 August report describes a mobile laboratory at Kasenyi near Tchomia, deployed on 23 July. Diagnostic time fell from as much as five hours to about one, more than 20 samples were processed in the first days, nine Congolese laboratory professionals were involved, and laboratories able to confirm Ebola increased from 2 to 18.
WHO AFRO: infection prevention and control in health facilities
The 30 July report says that WHO teams supported more than 900 health facilities and trained over 1,000 health workers. This is an operational response milestone, not a new epidemiological count.
DRC INSP: treatment centre in Rwankole
The 4 August report describes construction of a treatment centre with capacity for more than 100 beds in Rwankole and training for more than 150 hygiene workers. This is operational strengthening of the response, not a new epidemiological count.
WHO AFRO Weekly External Situation Report 11
This older weekly report with data as of 26 July first described the event as the largest recorded outbreak caused by Bundibugyo virus. The current comparative assessment comes from report 15.
WHO AFRO: The virus will not wait. Neither can we.
The 17 July statement says that more than 80% of new cases were detected outside known contact lists, around two thirds of deaths occurred in communities, and facilities in the hardest-hit areas were at or near capacity. Its numerical example is explicitly dated 16 July, so it does not replace the newer WHO AFRO report 15.
WHO DON613
Published on 17 July, WHO DON613 confirms 2,124 cases and 828 deaths in the DRC as of 15 July, 46 affected zones, ongoing transmission and the start of Uganda's 42-day countdown. WHO cautions that newly reported cases and deaths may include retrospective sample processing and data harmonisation. It reports at least 410 recoveries including the patient treated in Germany; the synchronised WHO table 20260717 reports 409 for the DRC, Uganda and France.
WHO: PARTNERS trial enrolment
A 2 July report states that patient enrolment has begun in the PARTNERS platform randomised trial in the DRC. The trial evaluates MBP134 and remdesivir, alone and in combination, in confirmed cases of disease caused by Bundibugyo virus. We use it for the formulation “clinical evaluation of candidate therapeutics”, not for a claim about approved treatment.
WHO: first BDBV diagnostic test in Emergency Use Listing
A 2 July report states that the first molecular diagnostic test for Bundibugyo virus has been added to WHO Emergency Use Listing and that DRC laboratory capacity has expanded to 10 laboratories with reported capacity above 2,000 tests per day. This is diagnostics, not a vaccine or treatment.
INRB / ANRS MIE–Inserm / ALIMA: EBO-PEP
A 14 July report announces the launch of a trial of obeldesivir as post-exposure prophylaxis in the DRC and Uganda. Recruitment begins in Ituri; nearly 1,000 asymptomatic participants older than 12 are planned after direct contact with a confirmed case in the preceding five days. Obeldesivir is investigational, not approved or proven effective prophylaxis.
WHO target product profile for BDBV vaccines
Published on 14 July, this document sets minimum and preferred characteristics for future vaccine candidates against disease caused by Bundibugyo virus. It is a research and development profile, not approval of a specific vaccine or evidence of efficacy.
WHO TAG-CVP: evaluation of Ervebo for research against BDBV
The advisory report published on 7 August following the 31 July meeting recommends prioritising a Phase III evaluation of Ervebo against BDBV without a preceding Phase II. It explicitly draws in part on preliminary, unpublished and non-peer-reviewed evidence; it is not approval, proven efficacy, routine deployment or WHO policy.
UN operational briefing on the response
The 14 July briefing reports 11 decentralised laboratories, 22 treatment centres and 7 transit centres. Its statement of 49 days without a new confirmed case applies to South Kivu, not to the outbreak as a whole.
Singapore CDA contribution to the response
On 14 July, Singapore announced a US$2 million contribution through Africa CDC and WHO for laboratory work, contact tracing, infection prevention and control, and clinical care in the DRC and Uganda.
DRC INSP / COUSP SitRep 50
Previous public DRC figures: status as of 3 July, INSP page published on 4 July. It reports 1,528 confirmed cases, 492 deaths among confirmed cases, 239 recovered and 628 people hospitalised in isolation. For 3 July, 26 newly confirmed cases were reported, including 9 deaths among them.
DRC INSP / COUSP SitRep 49
Previous public DRC figures: status as of 2 July, INSP page published on 3 July. It reports 1,502 confirmed cases, 473 deaths among confirmed cases, 229 recovered and 628 people hospitalised in isolation. For 2 July, 42 newly confirmed cases were reported, including 7 deaths among them.
DRC INSP / COUSP SitRep 48
Previous public DRC figures: status as of 1 July, INSP page published on 3 July. It reports 1,460 confirmed cases, 452 deaths among confirmed cases, 213 recovered and 641 people hospitalised in isolation. For 1 July, 54 newly confirmed cases were reported, including 9 deaths among them.
DRC INSP / COUSP SitRep 46
The previous public DRC figures: status as of 29 June, published on the INSP website on 1 July. It reports 1,333 confirmed cases, 399 deaths among confirmed cases, 189 recovered, 609 people hospitalised in isolation and contact tracing at 82.7%. Compared with the current SitRep 102, this is an older interim status.
DRC INSP / COUSP SitRep 42
An interim DRC status: data as of 25 June, published 26 June. It reports 1,203 confirmed cases, 321 deaths among confirmed cases, 148 recovered, 419 people in isolation or hospital and contact tracing at 82.8%. For 25 June, 48 confirmed cases were newly reported.
DRC INSP / COUSP SitRep 41
The previous public DRC interim status: status as of 24 June, published 25 June. It reports 1,155 confirmed cases, 304 deaths among confirmed cases, 138 recovered, 385 people in isolation or hospital, 34 affected health zones and contact tracing at 79.2%. For 24 June, 37 confirmed cases were newly reported; these are newly reported figures, not automatically new infections.
Uganda MoH dashboard
The official Ugandan overview as of 28 July reports 20 confirmed cases, 15 imported and 5 local, 2 deaths, 18 recovered, 0 current admissions, 831 all-time contacts listed, 0 active contacts under follow-up and 821 contacts that completed 21-day follow-up. The official daily series reports no new confirmed case after 21 June.
Uganda MoH: national “officially Ebola-free” declaration, 28 July
The ministry declared the national outbreak over on the basis of fully documented importation, reconstructed transmission chains, completed 21-day contact follow-up and no unexplained community transmission under enhanced surveillance. The national decision is not extended to the DRC or to the PHEIC status.
WHO AFRO: Uganda begins countdown to the end of the outbreak
The 16 July report confirms the last patient's second negative test and discharge and the start of the 42-day countdown. On 18 August, WHO subsequently stated publicly that Uganda had stopped transmission, and report 14 records 31 days without a new confirmed case; a separate formal WHO statement confirming the exact national declaration of 28 July was not located.
Uganda MoH: 42-day countdown explanation
A Ugandan update published on 4 July explains that the 42-day countdown before declaring the Ugandan outbreak over starts only once the last confirmed patient can no longer spread the virus. If a new case linked to ongoing transmission in the DRC appears, the countdown is reset.
ECDC outbreak page: previous snapshot from 7 August
This previously recorded state of the live page was updated on 7 August at 15:40 and used DRC data as of 5 August. It reported 4,053 cases, 1,850 deaths, 694 patients in isolation and 53 affected health zones. The current status with data as of 22 August is listed above.
UKHSA: precautionary medical evacuation after a potential exposure
The official 21 July report states that a UK resident working for a humanitarian organisation was precautionarily evacuated to the United Kingdom after a potential health-care-related exposure in the DRC. The person remained asymptomatic and was monitored in isolation; this was not a confirmed case, and UKHSA assessed the risk to the public as low.
WHO Europe: preparedness of European hospitals
The 27 July report confirms the precautionary transport of the UK resident on 22 July and reviews Czech and German experience with safe transport, isolation and care. The UK resident was asymptomatic; the article does not change the number of confirmed European cases.
Viruses: review of diagnostics and investigational countermeasures for BDBV
A peer-reviewed review accepted on 14 July and published on 15 July summarises diagnostics, candidate vaccines and therapeutic research for disease caused by Bundibugyo virus. We include it as an expert review source, not as a substitute for primary epidemiological or clinical sources and not as evidence of a new approval or demonstrated efficacy.
ECDC interim case definition for EU/EEA reporting
Published on 10 July, this document sets clinical, epidemiological, laboratory and exposure criteria for reporting and classifying cases in the EU/EEA. It is a terminology and surveillance source, not a new outbreak count.
ECDC: first imported case in Europe
A report of 24 June on the imported confirmed case in France in a physician returning from the DRC. ECDC states that the risk of sustained transmission in the EU/EEA is very low given early detection, isolation and care.
WHO DON608
An older WHO Disease Outbreak News item published on 19 June with DRC data as of 17 June and Uganda as of 18 June. It reports a total of 915 confirmed cases, of which the DRC 896 and Uganda 19, and notes that part of the increase in the DRC is linked to the scaling-up of testing and the retrospective processing of previously collected samples. The numbers are older than WHO daily update 20260717 and later national figures for the DRC and Uganda.
WHO EPI-WIN: safe, scalable Ebola (Bundibugyo) care
A WHO expert webinar scheduled for 24 June on care operations, clinical recommendations and the design of treatment centres in the DRC. It serves as operational and clinical context, not as a new numerical status or an announcement of an approved specific therapy.
WHO TAG-TP: immunomodulators and host-directed therapies
A 26 June statement noting that patient data on BVD pathogenesis are still lacking and that EBOV experience alone is not enough to select immunomodulatory or host-directed candidates for BVD clinical trials.
DRC INSP: PANTHER clinical study
A 29 June report announcing the launch of the PANTHER clinical study and team training in Bunia, Ituri. It concerns the evaluation of a candidate antiviral treatment for disease caused by Bundibugyo virus, not an approved specific therapy.
US CDC: confirmed US patient infected in the DRC
A 10 July statement on a US citizen working for a humanitarian organisation in the DRC who tested positive for Bundibugyo virus. The patient was subsequently medically evacuated under controlled conditions to Frankfurt. This is not transmission in the USA or Germany.
German BMG: patient in Frankfurt
The official German source reports admission to a special isolation unit in Frankfurt on 13 July and states that there is no risk to the public or other patients.
University of Oxford: first volunteer in the ChAdOx1 BDBV trial
A 24 July report confirms the first administration of the candidate vaccine to a human. The Phase I trial is planned to enrol 50 healthy adults aged 18–55 and assesses safety and immune response; this is not evidence of efficacy, an approved vaccine or public vaccination.
CEPI: ChAdOx1 BDBV
Confirms the first Bundibugyo virus vaccine candidate to enter Phase I. The figure of approximately 620,000 stockpiled doses refers to an investigational candidate for possible future study use, not a licensed vaccine.
UK Health Research Authority: regulatory review
Reports submission on 24 June, an accelerated ethics review and a final opinion on 13 July. This is procedural and regulatory context for a trial, not vaccine approval for public use.
WHO scientific update of 17 July
The technical meeting on medical-countermeasure research and development took place on 17 July. During the 11 August check, the page still contained no recording, presentations or published results; no new conclusion is inferred from the programme.
US CDC: returning travelers
The 12 August update and review distinguishes travellers after a stay in the DRC from those who were only in Uganda or South Sudan. Travellers who were in the DRC within 21 days before a flight may not board commercial flights to the United States; US citizens and nationals who were only in Uganda or South Sudan enter through designated airports for enhanced screening. CDC's renewed order of 12 August is in effect for 30 days. This is the US legal and travel context, not a Czech or European rule.
WHO outbreak hub
WHO's central gateway for the outbreak in the DRC and Uganda.
WHO: Ebola vaccines Q&A
Terminological and vaccination guidance updated on 25 June: it distinguishes EBOV/EVD, SUDV/SVD and BDBV/BVD, states that the licensed WHO-prequalified vaccine relates to disease caused by EBOV, and that there is no licensed vaccine for BVD. At that time it did not recommend Ervebo for BDBV response; the newer operational context is the WHO/Africa CDC allocation of 20 August, which does not change licensing or prove efficacy against BDBV.
WHO clinical recommendations for filovirus diseases
A clinical recommendation of 11 June for filovirus diseases including Bundibugyo; support for supportive care and clinical monitoring, not an announcement of an approved specific treatment for BVD. The executive summary was published on 15 June and WHO communicated the recommendations in a news release of 17 June.
WHO news: filovirus clinical guidelines
A news release of 17 June emphasising early supportive care and explicitly stating that, in the absence of licensed vaccines and treatment for Marburg, Bundibugyo and Sudan, early supportive care improves survival.
WHO DON607
A technical update published on 13 June; it reports the DRC as of 10 June and Uganda as of 10/11 June, contacts, risk assessment, a note on the retrospective processing of samples and the preparation of a clinical trial of candidate therapeutics. After DON608 and the more recent national figures of 19/21/22 June, it is no longer the main numerical status.
WHO / Africa CDC: continental response plan
A joint continental response plan for June–November 2026, published 5 June; a budget of USD 518 million and a “One Response” approach.
WHO AFRO: regional preparedness meeting in Uganda
A 27 June report on a regional preparedness meeting in Uganda focused on preparedness, points of entry, surveillance and simulations. It is preparedness context, not a new numerical status of the outbreak.
WHO AFRO / Africa CDC: Continental IMST
A report published on 27 June and modified on 30 June describing the launch of the joint Continental Incident Management Support Team in Kampala; the team is to be fully operational from 29 June. This is an operational and coordination source, not a new numerical status of the outbreak.
WHO AFRO Weekly External Situation Report 07
A weekly report published on 1 July using data as of 28 June; it is numerically older than WHO daily update 20260717 and SitRep 65. It is useful mainly for weekly context: Uganda reported no new confirmed cases over the previous week, while confirmed cases and deaths increased in the DRC and Mandima appeared among affected health zones.
WHO Director-General briefing, 2 July 2026
Clinical and operational context: WHO reports 1,406 confirmed cases and 438 deaths in the DRC, an average of 38 newly confirmed cases per day over the previous two weeks, expansion of laboratory capacity to 10 laboratories and the start of a clinical trial of MBP134 and remdesivir. It also mentions a security attack on a treatment centre in Ituri and a separate confirmed Marburg case in Uganda; Marburg is not part of the BDBV outbreak counts.
WHO DON605
Technical context published on 29 May; it is not the most recent main numerical figure.
ECDC risk classification and contact tracing
A recommendation of 15 June for the classification of exposure and the procedure for travellers or workers returning from affected areas.
ECDC importation risk model
A model of 15 June estimating a very low likelihood of importation of BDBV into the EU/EEA in the period 11–25 June; it is a model with uncertainties, not a guarantee of zero risk.
ECDC modelling overview
An overview of modelling evidence of 17 June stating that the true size of the outbreak may be higher than the reported counts, but the estimates are highly uncertain due to data limitations.
ECDC preparedness checklist
A preparedness overview published on 18 June and updated on 10 July for EU/EEA states in the event of a potential imported case. It assesses the importation risk as low and the overall risk to the general EU/EEA population as very low.
ECDC: airport exit screening fact-finding mission
A 29 June report on the EU Health Task Force mission of 15-21 June at N'djili airport in Kinshasa and Entebbe airport. ECDC says exit screening helps identify symptomatic travellers and reduce onward spread, but cannot fully prevent exportation of cases because symptoms may start after travel.
ECDC: Ebola disease awareness
A communication leaflet published on 30 June for communities at risk. It is a supporting source for public communication and misinformation work, not a new epidemiological count.
ECDC IPC advice
Rapid advice of 2 June on infection prevention and control in European healthcare facilities.
DRC INSP SitRep 22
A DRC national situation report published on 6 June; an older status retained only for the timeline.
Africa CDC PHECS
Continental emergency and regional coordination.
Czech official and supporting sources
Czech Public Health Service: response to a suspected highly dangerous infection
The official statement covers the controlled transfer and precautionary isolation of a woman after her return from Uganda on 1 August; the authorities said there was no risk to the public. (in Czech)
Minister of Health: test results
The official statement of 2 August reports negative laboratory results for Ebola and other highly dangerous infections. (in Czech)
iROZHLAS: suspicion in a woman returning from Uganda was not confirmed
Supporting news evidence for the negative results on 2 August; the woman remained at Bulovka University Hospital while another diagnosis was being determined. (in Czech)
Czech Ministry of Health (MZd ČR)
Precautionary admission of a US physician after a risk contact. (in Czech)
SZÚ: update of 3 June 2026
The Czech official overview of the epidemic in the DRC and Uganda; it serves as Czech context, but numerically works with an older status. (in Czech)
Czech Ministry of Foreign Affairs (MFA): Uganda
At the 26 August check, this travel advisory was marked “Still in force: 26 August 2026”; its substantive advice remained unchanged and had not reflected Uganda's national declaration of 28 July. (in Czech)
Czech Ministry of Foreign Affairs (MFA): DRC
At the 26 August check, this travel warning for Congo (Kinshasa) was marked “Still in force: 26 August 2026” and its substantive advice remained unchanged, including the occurrence of Ebola and the risk in Ituri, North Kivu and South Kivu. (in Czech)
Bulovka University Hospital
The official description of the Czech civilian capacity for the isolation and treatment of highly dangerous infections. (in Czech)
Czech MoD/VZÚ: Těchonín
The official description of the military capacity for biological protection, quarantine, decontamination and isolation in cases of highly dangerous infections. (in Czech)
iROZHLAS/ČTK: Těchonín
A supporting media record of the precautionary isolation of a Czech soldier after returning from a UN mission in the DRC; without symptoms. (in Czech)
Expert and sequencing sources
virological.org: initial genomes
The first genomes and updates of the sequencing analysis.
virological.org: molecular evolutionary analysis
A preliminary re-analysis of 10 sequences linked to the current outbreak, available as of 28 May; useful for a cautious reading of the time tree and uncertainties.
virological.org: genomic epidemiology, 9 July 2026
The initial dataset of the INRB-led analysis includes 139 DRC genomes sampled from 2 May to 23 June across 16 health zones; after quality control, individual phylogenetic analyses use smaller subsets. Two models place the common ancestor on 8 March (interval 1 February–5 April) and 15 March (9 February–12 April), respectively. These are uncertain retrospective model estimates, not a precise outbreak start date.
Pathoplexus Ebola-BDBV
A public sequence database for BDBV, including historical records. At the 26 August check, LAPIS aggregation showed 677 versioned database entries for outbreak Bdbv-2026: 655 from the DRC, 20 from Uganda and 2 from Germany, unchanged from the previous published version. The database count is not a clinical case count, the number of genomes in one analysis or evidence of a mutation changing viral properties.
Moderna: first participants in the mRNA-1469 trial
The 4 August release reports the first administration of the mRNA vaccine candidate in a Phase I trial in Canada. The objectives are safety, tolerability and immune response; this is not an approved or proven effective vaccine.
ClinicalTrials.gov NCT07737717
The primary registry record for mRNA-1469 lists an estimated enrolment of 84 healthy adults aged 18–65 at three Canadian sites. The update posted on 11 August lists the study as recruiting: the Truro site is recruiting and two other sites are not yet recruiting. This is Phase I research, not approval or proof of efficacy.
Pathoplexus LAPIS: aggregation by outbreak
Machine-readable control source for database counts: Bdbv-2007, Bdbv-2012, one unassigned record and Bdbv-2026. We use it only as a database total, not as a phylogenetic conclusion.
Pathoplexus LAPIS: aggregation by outbreak and country
Machine-readable control source for the country split of versioned Bdbv-2026 database entries. At the 26 August check it listed 655 entries from the DRC, 20 from Uganda and 2 from Germany.
ICTV Filoviridae profile
The taxonomic framework for the genus Orthoebolavirus.
Nature Medicine: Uganda index case
A short scientific communication published on 11 June 2026; a new publication of an older Ugandan event with a clinical profile, RT-qPCR confirmation of BDBV and 99% genome coverage on sequencing.
Nature Medicine: case treated in Berlin
The peer-reviewed accepted manuscript published on 24 August describes a 39-year-old health worker infected in Ituri who, after medical evacuation, received investigational MBP134 antibodies, remdesivir and supportive care and was discharged on day 22. A single case does not establish efficacy, safety in a larger population or approval; the manuscript will still undergo editorial changes before its final version.
WHO Weekly Epidemiological Record, volume 101, issue 33
Expert context published on 21 August uses data through 16 August and describes delayed recognition of early cases and the need for broader diagnostics after an EBOV-specific test was negative. Because its data cut is older, it is not used for current totals.
The Lancet Infectious Diseases: recalibrated stochastic model
A modelling study published online on 25 June 2026, DOI 10.1016/S1473-3099(26)00320-8. It calibrates the model to 598 confirmed cases as of 8 June and estimates cross-border spillover risk for preparedness. We use it as modelling and planning context, not as a current outbreak count.
Zhang et al., PNAS 2026: multivalent mRNA vaccine
A preclinical study of a multivalent mRNA vaccine platform against orthoebolaviruses, commented on in Nature Biotechnology on 16 June. Useful as research context for future broad-spectrum vaccines, not as evidence of an available or licensed vaccine for Bundibugyo in the current response.
Emerging Infectious Diseases: cross-reactive antibodies in serum samples collected from ferrets
A preclinical study of serum samples collected from ferrets after immunisation with an Ebola virus vaccine. Useful as laboratory research context on cross-reactivity, not as evidence of human effectiveness or a change in WHO's recommendation for BDBV.
Wamala et al., 2010
A description of the 2007 Ugandan Bundibugyo outbreak.
Media and further context
Aktuálně.cz / ČTK: claim that the outbreak began in February
The Czech article of 10 August carries a ČTK report based on the original AP report. AP quotes WHO Regional Director for Africa Mohamed Yakub Janabi; we found no separate official transcript. INRB and CDC models support a possible February start, but no exact date was directly observed. The suggestion that some early cases may have been mistaken for malaria or typhoid remains supported by the WHO quotation in AP rather than a separate official document.
Associated Press: latest DRC government update as of 28 July
On 30 July, AP reported the government status as of Tuesday 28 July: 3,442 cases and 1,521 deaths. A corresponding public SitRep 75/76 was not found at the 11 August check, so the figures remain explicitly attributed. AP also reports that Africa CDC attributed part of the increase to a backlog of cases and deaths.
Reuters: patient admitted in Frankfurt
A supplementary media source shared by Jan Pačes. For the main claims about infection acquired in the DRC, controlled medical evacuation and absence of risk to the public, we give precedence to CDC, the German BMG and ECDC.
UNICEF: community volunteers and U-Report survey
An article published on 13 July reports results from a May survey of approximately 50,000 respondents: 64% did not understand transmission, 63% did not know how to protect themselves, and around one in five did not believe the disease existed. We use it for communication context, not current epidemiological counts.
AP: protest by workers at the Rwampara treatment centre
A 13 July media report about a protest over unpaid salaries and bonuses. We do not treat it as an official national operational status because it is not newly confirmed in the latest SitRep or WHO update; it is listed only as supplementary context.
ČTK / Seznam Zprávy: Bulovka
Czech agency context on the discharge of the US physician from precautionary isolation on 10 June; he did not develop the disease. (in Czech)
Charité: Berlin
The official German context on the confirmed patient treated at the Charité; a report of 6 June states that the patient and his family contacts were discharged after isolation/quarantine was lifted.
dpa / Süddeutsche Zeitung: discharge from the Charité
A German agency report of 6 June states the same as a supplementary media source; the Charité takes official precedence.
Le Parisien / AFP: French patient discharged
A supplementary media source of 4 July; according to AFP, citing the French health minister, the first French case had been discharged after two negative PCR tests. For numerical totals we keep WHO/ECDC as primary; the WHO daily table 20260717 lists France as 1 imported confirmed case and 1 recovered as of 6 July.
Radio Okapi / Actualité.cd / Bunia Actualité: Nia-Nia
Local and DRC media sources from 6–7 July on 17 positive results from 20 earlier samples in the Nia-Nia health zone. We use them as a cautious addition to the operational context, not as a replacement for official WHO/INSP totals. Supporting links: Actualité.cd, Bunia Actualité.
New York Times: Bundibugyo treatment context
A supplementary journalistic piece on the treatment context of the current outbreak, shared as useful reading. We base expert claims about indications, candidate products and regulatory status in the text primarily on WHO and FDA.
Science: first treatment trial for Ebola Bundibugyo in the DRC
A secondary science-news article on the start of the PARTNERS trial. For precise wording on enrolment, evaluated candidates and the absence of approved treatment, we rely primarily on the WHO 2 July report; Science is useful only as supplementary context.
ČT24: transport and isolation
A description of the controlled transport and isolation regime. (in Czech)
MSF Ituri crisis
The humanitarian and operational context of the crisis in Ituri.
AP: Uganda closes border
Media context on the temporary closure of the border with the DRC.
PolitiFact
An analysis of misleading claims around the current outbreak.
Dated sources and how to work with them
For rapidly changing counts we give the publication date of the source and the day to which the data refer. Below is an overview showing which source underpins each part of the text and which sources serve mainly as context.
Associated Press: DRC government status as of 28 July 2026
On 30 July, AP published figures attributed to the latest DRC government update: 3,442 cases and 1,521 deaths. A corresponding public primary SitRep 75/76 was not found on the INSP website at the 11 August check. The figures therefore remain explicitly attributed to the media report and government source; the article is not used to derive daily values or additional epidemiological categories.
DRC INSP / COUSP SitRep MVB RDC 102
The latest publicly found detailed DRC report during the 26 August check is SitRep 102 with data as of 24 August: 5,656 confirmed cases, 2,715 confirmed deaths, 1,245 recoveries, 792 patients in isolation or treatment centres and 58 affected health zones. SitReps 101–102 are the latest two time-series points; their daily values are transcribed directly rather than derived from cumulative differences.
DRC INSP / COUSP SitRep MVB RDC 080
Data as of 2 August, published on 3 August: 3,802 confirmed cases, 1,707 deaths among confirmed cases, 727 recovered, 707 people in isolation and follow-up of 79.2% of listed contacts. The report states 58 newly confirmed cases and 19 recoveries. Its headline figure, cumulative arithmetic and ECDC support 40 daily deaths, while one narrative sentence says 37; the report separately records harmonisation of 10 earlier deaths.
DRC INSP / COUSP SitRep MVB RDC 057: Tshopo and Haut-Uele
The SitRep integrates Tshopo and Haut-Uele among affected provinces for the first time. Tshopo has four confirmed cases and two deaths; Haut-Uele has one confirmed case and one death. All five cases are epidemiologically linked to Nia-Nia and had already been included under Ituri, so the national total of 1,873 is deduplicated. Suspected cases in Boma Mangbetu, Pawa and Isiro await INRB confirmation.
DRC INSP / COUSP SitRep MVB RDC 050
Previous public DRC figures: data as of 3 July, INSP page published on 4 July. It reports 1,528 confirmed cases, 492 deaths among confirmed cases, 239 recovered, 628 people hospitalised in isolation and contact tracing at 81.5%. For 3 July, 26 newly confirmed cases were reported, including 9 deaths among them.
DRC INSP / COUSP SitRep MVB RDC 049
Previous public DRC figures: data as of 2 July, INSP page published on 3 July. It reports 1,502 confirmed cases, 473 deaths among confirmed cases, 229 recovered, 628 people hospitalised in isolation and contact tracing at 81.8%. For 2 July, 42 newly confirmed cases were reported, including 7 deaths among them.
DRC INSP / COUSP SitRep MVB RDC 048
Previous public DRC figures: data as of 1 July, INSP page published on 3 July. It reports 1,460 confirmed cases, 452 deaths among confirmed cases, 213 recovered, 641 people hospitalised in isolation and contact tracing at 82.7%. For 1 July, 54 newly confirmed cases were reported, including 9 deaths among them.
DRC INSP / COUSP SitRep MVB RDC 046
The previous public DRC figures: data as of 29 June, published on the INSP website on 1 July. It reports 1,333 confirmed cases, 399 deaths among confirmed cases, 189 recovered, 609 people hospitalised in isolation and contact tracing at 82.7%. Compared with the current SitRep 102, this is an older interim status.
DRC INSP / COUSP SitRep MVB RDC 044
An older public DRC status: data as of 27 June, published 28 June. It reports 1,274 confirmed cases, 360 deaths among confirmed cases, a current case-fatality ratio of 28.3%, 178 recovered, 502 people in isolation or hospital, 35 affected health zones, 239 suspected cases on the day including 70 suspected deaths, and contact tracing at 87.1%. For 27 June, 47 confirmed cases including 12 deaths were newly reported; a separate item of 10 deaths in treatment centres in Ituri must not be added as extra daily deaths in the chart. Mandima in Ituri was newly affected.
WHO Alert and response: daily epidemiological update 20260824
At the 26 August check, the country rows list the DRC at 5,514/2,642/1,200 as of 22 August, Uganda at 20/2/18 as of 21 July and France at 1/0/1 as of 6 July. The Total row agrees with the country sum: 5,535 confirmed cases, 2,644 confirmed deaths and 1,219 recoveries. The countries have different cut-off dates.
WHO AFRO Weekly External Situation Report 15, data as of 23 August 2026
The weekly status reports 5,584 confirmed cases and 2,680 confirmed deaths in the DRC, 563 cases and 302 deaths more than report 14. WHO describes sustained transmission, high mortality and continuing geographic expansion. Newer SitRep 102 supplies the more recent national numerical status; the weekly report is used for its trend assessment.
WHO Director-General's opening remarks at the second IHR Emergency Committee meeting, 18 August 2026
Primary support that the second meeting was held, for WHO's assessment of continued risk, and for the interim clinical-trial status: two BDBV-specific vaccines had entered human trials and PARTNERS had enrolled 100 patients. These are opening remarks, not the Committee decision, an efficacy result or an approval.
WHO AFRO: The virus will not wait. Neither can we, 17 July 2026
WHO describes operational pressure: more than 80% of new cases were detected outside known contact lists, around two thirds of deaths occurred in communities, and facilities in the hardest-hit areas were at or near capacity. The numerical example in the statement is dated 16 July; newer headline counts therefore come from WHO AFRO report 15.
Radio Okapi: 17 new confirmed cases in Niania, 7 July 2026
A supporting DRC media source. Radio Okapi reports that the information was provided on 6 July by health-zone lead Joseph Pemanakue: 17 cases were confirmed after analysis of 20 samples collected from 20 June, which reached the Bunia laboratory with a delay of about two weeks. We present this as newly laboratory-confirmed results from older samples.
Actualité.cd: Nia-Nia and operational response constraints, 7 July 2026
A supplementary media source on the same event. It reports 17 positive results from 20 samples transported to Bunia on 4 July, a cumulative 29 confirmed cases in the Nia-Nia health zone since late May, and the context of logistical difficulties, attacks on health facilities, insecurity and protest action/strike movements by field teams. We read it as operational context, not as an official national SitRep.
Bunia Actualité: delayed sample transport to Bunia, 6 July 2026
A local Ituri source reporting that 20 samples reached Bunia on 4 July and 17 were positive; it gives 5 July as the confirmation date. It also lists affected areas within Nia-Nia and reports a cumulative 29 confirmed cases since late May. For headline totals we continue to use official WHO/INSP/ECDC sources.
DRC INSP / COUSP SitRep MVB RDC 042
An interim DRC status with data as of 25 June, published 26 June. It reports 1,203 confirmed cases, 321 deaths among confirmed cases, a current case-fatality ratio of 26.7%, 148 recovered, 419 people in isolation or hospital, 34 affected health zones, 265 suspected cases on the day including 77 suspected deaths, and contact tracing at 82.8%. For 25 June, 48 confirmed cases were newly reported.
DRC INSP / COUSP SitRep MVB RDC 041
A previous public DRC status: data as of 24 June, published 25 June. It reports 1,155 confirmed cases, 304 deaths among confirmed cases, a current case-fatality ratio of 26.3%, 138 recovered, 385 people in isolation or hospital, 34 affected health zones, 154 suspected cases on the day including 40 suspected deaths, and contact tracing at 79.2%. For 24 June, 37 confirmed cases were newly reported; Ituri had 1,054 confirmed cases and 250 deaths, North Kivu 98 and 53, South Kivu 3 and 1.
DRC INSP / COUSP SitRep MVB RDC 040
An interim DRC status with data as of 23 June, published 24/25 June. It reports 1,118 confirmed cases, 291 deaths among confirmed cases, 122 recovered, 408 people in isolation or hospital, 138 suspected cases on the day including 45 suspected deaths, and contact tracing at 77.1%.
DRC INSP / COUSP SitRep MVB RDC 039
A previous public DRC status: data as of 22 June, published 23 June at 21:45. It reports 1,094 confirmed cases, 277 deaths among confirmed cases, a current case-fatality ratio of 25.3%, 115 recovered, 387 people in isolation or hospital, 34 affected health zones and 8,278 contacts under follow-up. For 22 June, 46 confirmed cases including 10 deaths were newly reported; 43 of them were in Ituri and 3 in North Kivu. Ituri had 997 confirmed cases and 226 deaths, North Kivu 94 and 50, South Kivu 3 and 1.
DRC Ministry of Communication and Media: point de situation Ebola, 21 June 2026
An older DRC government status as of 21 June. The official communication channel reported 1,048 confirmed cases, 267 deaths, 112 recovered and 371 people in isolation or hospital. It serves as the previous status before INSP SitRep 39 of 22 June.
BETO/AFP: Ebola RDC, bilan officiel au 21 juin
A media transcript of the government situation report published on 23 June at 00:29 WAT. It states that the government report published on 22 June and closed as of 21 June has 1,048 confirmed cases and 267 deaths after cleaning and harmonising the DHIS2 database, along with 371 people in isolation or hospital, 112 recovered and contact tracing at 70.8%. This is a supporting transcript of the government report, not a replacement for WHO/ECDC.
ECDC outbreak page: previous snapshot from 7 August 2026
This previously recorded state of the live page used DRC data as of 5 August and reported 4,053 cases, 1,850 deaths and 694 patients in isolation. The current status with data as of 22 August is listed at the start of the inventory.
Uganda Ministry of Health dashboard, status as of 28 July 2026
The official Ugandan dashboard reports 20 confirmed cases, 15 imported and 5 local, 0 current admissions, 18 recovered, 2 deaths, 831 all-time contacts listed, 0 active contacts under follow-up and 821 contacts with completed 21-day follow-up. A separate 28 July update declares national “officially Ebola-free” status. On 18 August, WHO stated publicly that Uganda had stopped transmission, and report 14 records 31 days without a new confirmed case; a separate formal WHO statement confirming the exact 28 July declaration was not located.
WHO Disease Outbreak News 2026-DON608
An older WHO DON, published 19 June; it works with DRC data as of 17 June and Uganda as of 18 June. It reports a total of 915 confirmed cases: the DRC 896 confirmed and 232 deaths, Uganda 19 confirmed and 2 deaths plus 1 probable case with death. WHO reports at least 88 recovered and notes that since DON607 the DRC has gained 220 confirmed cases and 96 confirmed deaths, with part of the increase linked to the scaling-up of testing and the retrospective processing of previously collected samples.
DRC INSP / COUSP SitRep MVB RDC 036
The public DRC status with data as of 19 June, published 20 June at 19:24. It reports 956 confirmed cases, 247 deaths among confirmed cases, a current case-fatality ratio of 25.8%, 92 recovered, 361 people in isolation or hospital and 34 affected health zones. For 19 June, 23 confirmed cases including 2 deaths were newly reported; by province, Ituri 874 cases and 201 deaths, North Kivu 79 cases and 45 deaths, South Kivu 3 cases and 1 death. After the government figures as of 21 June it is an older interim status.
DRC INSP / COUSP SitRep MVB RDC 035
An interim DRC status with data as of 18 June, published on the morning of 20 June. It reports 933 confirmed cases, 245 deaths among confirmed cases, 80 recovered, 416 people in isolation or hospital and 34 affected health zones. For 18 June, 36 confirmed cases including 12 deaths were newly reported.
DRC INSP / COUSP SitRep MVB RDC 034
An interim DRC status with data as of 17 June, published on the evening of 18 June. It reports 896 confirmed cases, 232 deaths among confirmed cases, 78 recovered, 383 people in isolation or hospital and 33 affected health zones. This status matches the DRC figures in WHO DON608 and in the CDC numerical module.
ECDC: outbreak page, 17 June 2026
The European page on the outbreak in the DRC and Uganda, updated 17 June at 14:30. It gives the European risk assessment: very low for people living in the EU/EEA. For the DRC it reports the status as of 15 June: 837 confirmed cases, 196 confirmed deaths and 376 people hospitalised in isolation. Geographically it reports Ituri with 767 confirmed cases across 20 health zones, North Kivu with 67 cases across 10 zones and South Kivu with 3 cases in one zone; no new health zones were added. For Uganda it reports 19 confirmed cases and 2 deaths as of 17 June; since the three cases reported on 5 June, no further new cases had been reported in Uganda. ECDC also describes a reported attack on a safe and dignified burial team in Mongbwalu and reports of five workers at entry/screening points being detained after a false accusation of spreading Ebola.
US CDC: current situation
A continuously updated summary of the US response. The page, updated on 19 August and expert-reviewed on 12 August, states that no case of Ebola has been confirmed in the USA linked to this outbreak and that the overall risk to the US public and travellers remains low. It describes the event as the second-largest Ebola outbreak on record; it recommends avoiding all travel to Ituri and North Kivu, avoiding nonessential travel to Haut-Uele and Tshopo, and taking enhanced precautions in other parts of the DRC and in Uganda.
US CDC: information for returning travelers, updated 19 August 2026
The US page for travellers, updated on 19 August and expert-reviewed on 12 August, says that travellers, including US citizens, who were in the DRC within 21 days before their flight may not board commercial flights to the United States. US citizens and nationals who were only in Uganda or South Sudan enter through designated airports for enhanced screening. CDC's renewed order of 12 August is in effect for 30 days. For the Czech site this is foreign legal and travel context; it cannot be transposed onto Czech or EU rules.
Uganda Ministry of Health: Ebola dashboard, 28 July 2026
The official Ugandan overview as of Tuesday 28 July: 20 cumulative confirmed cases, of which 15 imported and 5 local, 0 current admissions, 18 recovered, 2 deaths, 831 all-time contacts listed, 0 active contacts under follow-up and 821 contacts with completed 21-day follow-up.
ECDC: risk classification and contact tracing, 15 June 2026
A European recommendation for the classification of exposure and the procedure for people potentially exposed to Ebola after travel, stay or work in affected areas. It distinguishes people with no exposure, low-risk exposure and high-risk exposure; for low risk it recommends 21 days of self-monitoring of health status, and for high risk active monitoring, contactability, not travelling abroad and, depending on circumstances, limiting social contacts or clinical work.
ECDC: estimation of importation risk, 15 June 2026
A model of the importation of BDBV into the EU/EEA for the period 11–25 June. ECDC estimates approximately one importation per 23,000 travellers from the main outbreak area and the probability of at least one importation, given a hypothetical 100 travellers from this area, at 0.45%; according to ECDC the true probability will probably be lower. The conclusion: sporadic importation cannot be ruled out, but the model suggests a very low probability.
ECDC: modelling overview, 17 June 2026
An overview of available modelling evidence for the size and possible spread of the current outbreak. ECDC states that several modelling groups suggest the true size of the outbreak is higher than the reported counts; one model estimated cumulative infections as of 13 June at 3.0–10.2 times the reported cases in the 90% credible interval. At the same time ECDC emphasises high uncertainty due to data limitations, so the results serve as a planning framework, not a certain forecast.
The Lancet Infectious Diseases: size and cross-border spillover model, 25 June 2026
A recalibrated stochastic modelling study on the size of the outbreak and the risk of cross-border spillover from Ituri. The model is calibrated to 598 confirmed cases as of 8 June and is mainly a preparedness input; after WHO/INSP updates, we do not use it as a current case count.
ECDC: preparedness and response for imported cases, published 18 June and updated 10 July 2026
An operational preparedness overview for a potential imported case of Ebola into the EU/EEA health system. In it ECDC states that the overall risk of disease caused by Bundibugyo virus for the general EU/EEA population is very low and estimates the importation risk at approximately one importation per 24,000 travellers from the main outbreak area into the EU/EEA, with a 90% uncertainty interval of 13,000–54,000.
ECDC: fact-finding mission on airport exit screening, 29 June 2026
A report from the EU Health Task Force mission at N'djili airport in Kinshasa and Entebbe airport, conducted on 15-21 June. ECDC states that the exit-screening systems were functional and in line with international standards, but that screening cannot fully prevent exportation of cases because symptoms may start only after travel.
CDC MMWR: Notes from the Field, 5 June 2026
A CDC expert summary published on 5 June with data as of 2 June. It is useful mainly for context: this is the largest documented outbreak of Bundibugyo virus, the initial clusters affected health workers and the true extent may be greater than the confirmed counts. We therefore do not take it as the main numerical figure for this version.
CDC MMWR: modeled scenario projections, 5 June 2026
Modelled scenarios, not a certain forecast. Under the main assumption of 50 deaths before outbreak recognition, the model places zoonotic spillover around 19 February, with an interquartile range of 1 February–8 March; other assumptions shift the median to 8 February or 29 January. The scenarios also show that the resulting case count depends strongly on the speed of case finding, isolation and contact tracing. They therefore cannot be reduced either to a precise outbreak start date or to the sentence “CDC predicted 20,000 cases”.
CDC MMWR: risk assessment for the U.S. population, 5 June 2026
A risk assessment for the USA over the next three months. For our site it serves as supplementary context on the low risk outside the outbreak zone and on the emphasis on controlling the epidemic at source.
WHO: Ebola outbreak hub
WHO's central page for the outbreak in the DRC and Uganda, suitable as a gateway to the most recent official documents, briefings and technical materials.
WHO clinical recommendations for filovirus diseases, 11 June 2026
WHO's clinical recommendation for filovirus diseases including diseases caused by Ebola, Sudan, Bundibugyo, Taï Forest and Marburg viruses. It supports systematic clinical and laboratory monitoring, oral and intravenous fluid therapy, management of shock, vasopressors, management of suspected bacterial co-infection, the approach to haemorrhagic complications and the monitoring of survivors. It does not mean the approval of a specific targeted treatment for BVD.
WHO concise summary of clinical recommendations for filovirus diseases, 15 June 2026
A concise summary of WHO's clinical recommendations, suitable for a quick check of the main recommended areas of care: patient monitoring, fluids, management of shock, antimicrobial treatment in suspected co-infection, the approach to haemorrhage and the monitoring of survivors.
WHO: comprehensive filovirus guidelines news release, 17 June 2026
WHO's public news release on the new recommendations. For the current outbreak the key formulation is that, in the absence of licensed vaccines and treatment for Marburg, Bundibugyo and Sudan, early supportive care improves survival; for Bundibugyo, therefore, there is still no approved specific therapy.
WHO Disease Outbreak News 2026-DON607
A technical update published on 13 June. For the DRC it gives data as of 10 June: 676 confirmed cases, 136 confirmed deaths and 5,768 identified contacts, of which 4,141 were under follow-up. For Uganda it gives 19 confirmed cases, 2 deaths in imported cases, 1 probable case with death and 820 contacts as of 11 June. WHO states that there is no documented community transmission in Uganda, and repeats the note that newly reported confirmed cases and deaths in the DRC may be part of the retrospective processing of previously collected samples, not necessarily newly arising infections. DON607 is also important for the risk assessment and the clinical trial: WHO describes support for the implementation of a trial of MBP134 and maftivimab (REGN3479) for treatment and obeldesivir for post-exposure prophylaxis; the protocol is under ethical and regulatory review.
WHO Disease Outbreak News 2026-DON606
An official technical update published on 8 June with data as of 6 June. It reports a total of 534 confirmed cases and 93 confirmed deaths: the DRC 515 confirmed and 91 deaths, Uganda 19 confirmed and 2 deaths plus 1 probable case with death. For the DRC it reports 25 health zones with reported cases, 16 confirmed cases among health workers and 5,040 contacts under follow-up. WHO also notes that newly reported confirmed cases and deaths may be linked to the retrospective processing of previously unevaluated samples, and so need not be newly arising infections.
WHO EPI-WIN webinar, 9 June 2026
A WHO expert webinar on what is known about Ebola disease caused by Bundibugyo virus, including epidemiology, transmission, clinical features, country preparedness, community protection and points of entry. It serves as an interpretive and advisory source, not as a new numerical status of the outbreak.
WHO EPI-WIN webinar, 24 June 2026
An expert webinar on safe and scalable care for Ebola disease caused by Bundibugyo virus in the DRC, including the operation of treatment centres, clinical recommendations and the design of care. It serves as operational and clinical context; it is not a new epidemiological status at a given date nor confirmation of a specific approved treatment.
WHO TAG-TP: immunomodulators and host-directed therapies, 26 June 2026
A statement on immunomodulators and host-directed therapies for BVD. WHO notes that patient data on BDBV pathogenesis are still lacking and that evidence derived mainly from EBOV is not, on its own, enough to select such candidates for clinical trials.
DRC INSP: launch of the PANTHER clinical study, 29 June 2026
The official INSP report on the launch of the PANTHER clinical study and team training in Bunia, Ituri. We use it for the cautious formulation that a candidate antiviral treatment against disease caused by Bundibugyo virus is being evaluated; it does not mean that an approved specific BVD treatment exists.
WHO: daily epidemiological updates
The synchronised daily overview during the 11 August check is 20260810. It reports 4,230 confirmed cases and 1,918 confirmed deaths in total, using DRC data as of 7 August, Uganda data as of 21 July and France data as of 6 July. The country sum matches the Total row.
DRC INSP / COUSP SitRep MVB RDC 023
A DRC national situation report with data as of 6 June and publication on 7 June. It reports 515 confirmed cases, 91 confirmed deaths, 117 suspected cases on the day, 283 hospitalised/isolated and 12 recovered. For 6 June, 27 confirmed cases were newly reported in Ituri, including 4 deaths.
DRC INSP / COUSP SitRep MVB RDC 024
A DRC national situation report with data as of 7 June and publication on 8 June. It is already an older interim status: the DRC 550 confirmed cases, 101 confirmed deaths and 309 people hospitalised in isolation. Geographically it reports Ituri as the main outbreak with 518 confirmed cases, North Kivu with 29 cases and South Kivu with 3 cases.
DRC INSP / COUSP SitRep MVB RDC 025
A DRC national situation report with status as of 8 June and publication on 9 June. ECDC takes from it the DRC status of 598 confirmed cases, 115 confirmed deaths and 297 people hospitalised in isolation. Geographically it reports Ituri with 563 confirmed cases, North Kivu 32 and South Kivu 3. It serves as an interim status for the DRC data as of 8 June, not as the main numerical figure after the CDC update of 10 June.
WHO / Africa CDC: joint continental response plan, 5 June 2026
A publication and event of 5 June. The plan for June to November 2026 complements the national plans of the DRC and Uganda, has a budget of USD 518 million and covers coordination, epidemiological surveillance, laboratory testing, infection prevention and control, clinical care, community engagement, research, logistics and the protection of essential health services.
WHO Director-General opening remarks, 3 June 2026
A briefing after a visit to the DRC. WHO reports 344 confirmed cases and 60 deaths in the DRC, 15 confirmed cases and 1 death in Uganda, six recovered in the DRC and two in Uganda, contact tracing in the DRC at roughly 45%, and risk that is very high nationally, high regionally and low globally. WHO also explicitly states that the response is so far proceeding without approved vaccines and therapeutics for Bundibugyo.
WHO Disease Outbreak News 2026-DON605
A technical update published on 29 May: an increase in confirmed cases as of 29 May, 16 confirmed cases among health workers, laboratory data from the DRC, the dominance of Ituri, data on Uganda and a risk assessment of very high nationally in the DRC, high regionally and low globally.
WHO and the DRC government: joint statement
A joint statement published on 30 May on the response in the DRC, the need for clinical trials, open points of entry, cross-border information sharing and the financing of the response.
WHO Director-General briefing in Bunia
A briefing of 30 May on the need to interrupt transmission at source, safe burials, community work, supportive care and the reassessment of travel bans or border closures.
WHO: candidate treatments and vaccines
A report of 28 May on priority clinical trials: MBP134, maftivimab, remdesivir and a combination of a monoclonal antibody with remdesivir for confirmed cases, obeldesivir for the evaluation of post-exposure prophylaxis, and the investigational vaccines rVSV Bundibugyo and ChAdOx1 Bundibugyo. WHO emphasises that these products belong exclusively in clinical trials. The more recent DON607 of 13 June, when describing the protocol in preparation, names MBP134 and maftivimab, designated by the development code REGN3479, for treatment and obeldesivir for post-exposure prophylaxis; both sources should therefore be read with their date.
WHO: emergency guidance on Ervebo during BVD outbreaks
A WHO technical document of 28 May: the evidence on cross-protection of Ervebo against Bundibugyo is very limited and insufficient, so it is not intended for routine or blanket use outside a controlled research setting.
WHO TAG-CVP: evidence for use of Ervebo against BDBV
The advisory report published on 7 August summarises the 31 July meeting and recommends prioritising Ervebo for a Phase III trial without a preceding Phase II. Its evidence includes preliminary, unpublished and non-peer-reviewed data, and the report itself notes that it may not represent WHO policy. It is neither BDBV approval nor a recommendation for routine deployment.
WHO: message to the people of DRC
A public communication text by WHO of 28 May on community trust, early care, safe burials and the fact that there are not yet any approved specific vaccines or treatment for Bundibugyo.
WHO Disease Outbreak News 2026-DON603
An official WHO technical update as of 21 May: 83 confirmed cases in the DRC across 15 health zones of the provinces of Ituri, North Kivu and South Kivu, and 2 confirmed cases in Uganda.
WHO Disease Outbreak News 2026-DON602
An older official WHO technical document on the initial confirmation of the outbreak, the timeline and the first epidemiological data.
WHO PHEIC statement
The formal declaration of a public health emergency of international concern. WHO also stated that the event does not meet the criteria for a “pandemic emergency” under the International Health Regulations.
WHO temporary recommendations, 22 May 2026
The temporary recommendations of the WHO Emergency Committee: confirmation of the PHEIC, distinction from a pandemic emergency, a recommendation not to halt flights across the board, and a note that the GeneXpert platform does not detect Bundibugyo virus.
WHO Director-General ministerial briefing, 25 May 2026
An older but still useful WHO framing of the escalation of the response: rapid spread, more than 900 suspected cases, 220 suspected deaths, a continental incident management support team, USD 3.9 million from the emergency fund and the preparation of trials of candidate countermeasures.
WHO Rapid Risk Assessment v3
A rapid risk assessment published on 9 June. It extends the geographic framework to the DRC, Uganda and countries sharing a land border with states with documented detection of BDBV; it supports the formulations on very high risk in the DRC, high risk in Uganda and neighbouring border countries, and low global risk.
WHO AFRO Weekly External Situation Report 02
A weekly situation report with data as of 24 May: 390 further suspected cases since the previous report, an increase in confirmed cases in the DRC from 33 to 105 and 13 health zones with reported cases.
Uganda Ministry of Health: Ebola update, 2 June 2026
An official Ugandan update published on 2 June at 15:40 local time. We use it as confirmation of the older Ugandan status of 15 confirmed cases and 1 confirmed death; for the more recent Ugandan status we use the Uganda MoH dashboard as of 28 July. WHO daily epidemiological update 20260824 uses a separate Uganda data cut as of 21 July.
Uganda Ministry of Health: Ebola dashboard
The main Ugandan numerical source for this version. It gives the status as of Tuesday 28 July: 20 cumulative confirmed cases, of which 15 were imported and 5 local, 0 current admissions, 18 recovered, 2 cumulative deaths, 831 all-time contacts listed, 0 active contacts under follow-up and 821 contacts with completed 21-day follow-up.
Uganda Ministry of Health: press release, 25 May 2026
The official confirmation of two new cases of Ebola in Ugandan health workers from a private facility in Kampala; both are in a designated treatment facility and their contacts are being traced.
ECDC: previous snapshot of the live page from 7 August 2026
This previously recorded state of the live page used DRC data as of 5 August and reported 4,053 cases, 1,850 deaths and 694 patients in isolation. The current status with data as of 22 August is listed at the start of the inventory.
ECDC RAGIDA Ebola, 30 May 2026
An updated European recommendation for air travel: risk assessment and contact tracing in the event of a suspected or confirmed case of Ebola during or after a flight.
ECDC rapid advice on IPC, 2 June 2026
Rapid European advice for healthcare facilities: triage of a person with suspected infection, isolation from the onset of symptoms, multi-level infection prevention and control, and the use of high-level isolation where available.
DRC INSP SitRep MVB RDC 018
A DRC national situation report with data as of 1 June and publication on 2 June. WHO and ECDC previously used it for the DRC status of 344 confirmed cases, 60 confirmed deaths and 116 suspected cases; as of 24 June it is already only an older status.
DRC INSP SitRep MVB RDC 019
A DRC national situation report published on 3 June with data as of 2 June. ECDC previously took from it the DRC status of 363 confirmed cases, 62 confirmed deaths and 206 hospitalised/isolated people. As of 10 June it is an older status, not the main numerical figure.
Africa CDC KHub: Africa Epidemic and Outbreak Weekly Report, Issue 16
An operational weekly report marked 2 June 2026. It works with older and partly different operational figures, so we do not use it as the main numerical figure for this version. It is suitable for context on the continental response, cross-border coordination and the priorities of the outbreak response.
ECDC: Communicable Disease Threats Report, week 22
A weekly European overview for 24–30 May: it summarises the situation in the DRC and Uganda, imported suspected cases in Europe, ECDC's activities in infection prevention and control, and a recommendation to prioritise informing travellers over blanket entry screening.
ECDC: increased activities, 27 May 2026
A press release on the scaling-up of European support, daily epidemiological updates, the IPC recommendation in preparation, modelling of the likelihood of importation and cooperation with the aviation sector.
ECDC: threat assessment, 21 May 2026
A technical European risk assessment of 21 May: very low risk for the general EU/EEA population and low risk for travellers if measures are followed.
ECDC: EU Health Task Force
European expert support for the response: the deployment of an expert to Africa CDC and consideration of further experts depending on how the situation develops.
Africa CDC PHECS declaration
Continental emergency, regional coordination, population movement and operational risks in East Africa.
Africa CDC: position on US travel restrictions
Political and public-health context on travel restrictions, solidarity and the need to control the outbreak at source.
WHO AFRO: outbreak page
WHO's regional page on the active outbreak in the DRC, the cross-border risk and the mobilisation of research, including readiness for clinical trials and the emergency use of investigational countermeasures.
WHO AFRO: Kampala cross-border coordination communiqué
The output of a meeting of the DRC, Uganda, South Sudan, Africa CDC, WHO, UNICEF and partners in Kampala on 22–23 May on the cross-border coordination of the response.
DRC Ministry of Health: coordination in Kampala
A national official DRC source on the agreement of the DRC, Uganda and South Sudan on cross-border coordination, epidemiological surveillance, diagnostics, the protection of health workers and community communication.
CDC travel notice: Democratic Republic of the Congo
A level 3 travel advisory: avoid nonessential travel to Haut-Uele and Tshopo provinces.
CDC Level 4 travel notice: Ituri and North Kivu
CDC recommends avoiding all travel to Ituri and North Kivu except for humanitarian aid or emergency response.
CDC travel notice: Democratic Republic of the Congo and Uganda
The current combined CDC level 2 travel advisory for the DRC and Uganda. In the 29 June check, the URL redirected to a page retaining the enhanced-precautions content for Uganda and DRC provinces not affected by the outbreak and is complemented by a separate level 3 advisory for the most affected provinces of the DRC.
Government of Canada / PHAC: new temporary entry measures
Announced on 19 July and effective from 20 July at 11:59 pm EDT, the measure prohibits entry by foreign nationals who were in the DRC during the previous 21 days unless exempt under PHAC rules. Canadian citizens, permanent residents and other people authorized to enter may return; if they were in the DRC, Uganda or South Sudan during the previous 21 days, they undergo a health assessment and mandatory 21-day quarantine unless exempt from quarantine under PHAC rules. PHAC's detailed rules and exceptions and IRCC provide operational details. We present this as Canadian policy that differs from WHO temporary recommendations and Africa CDC guidance against blanket travel bans.
AP News: Uganda closes border with Congo
A media, rather than primarily official, source on the temporary closure of the Ugandan border with the DRC on 27 May. It is best read together with the note that WHO does not recommend blanket border closures.
AP News: displacement camp in Bunia
Reporting context of 27 May on conditions in the camp for displaced people in Bunia. Suitable for humanitarian context, not as a primary source of epidemiological counts.
AP News: aid supplies reach Bunia
Reporting context of 28 May on the arrival of humanitarian and medical supplies in Bunia, the shortage of equipment and operational difficulties in an unstable region.
MSF: Ituri's overlapping crises leave millions at risk
Humanitarian context on the overlapping of the epidemic, displacement and the security crisis in Ituri. MSF describes the risk of spread in places with large numbers of displaced people, the opening of a 48-bed isolation and treatment centre, and the impact of delays in supplies and staff.
České noviny / ČTK: man after contact with an Ebola patient
A Czech agency overview of the hospitalisation of the US physician after a risk contact, including the information that he is at Bulovka, without symptoms and in isolation. (in Czech)
České noviny / ČTK: Uganda reports two new cases
A Czech agency source of 25 May on the rise in the number of confirmed cases in Uganda to seven and on the two newly confirmed health workers in Kampala. (in Czech)
ČT24: transport and isolation at Bulovka
Czech public-service context on the controlled transport, decontamination at the airport, isolation regime and the hospital's statement that the patient was without symptoms. (in Czech)
ČT24: the risk of Ebola in Europe
An explanatory Czech text on why, with early isolation and protective procedures, the risk of further spread in European healthcare conditions is low. (in Czech)
Reuters: US doctor heading to Czech hospital
International agency context on the health worker, after contact with a patient in Uganda, heading to a Czech hospital for precautionary monitoring.
Bulovka University Hospital: National Centre for the Isolation and Treatment of Highly Dangerous Infections
The official description of the Czech civilian capacity for the isolation and treatment of highly dangerous infections, including bioboxes, a negative-pressure regime and laboratory facilities. (in Czech)
Czech Ministry of Foreign Affairs (MFA): Uganda – occurrence of Ebola
A practical travel advisory on the occurrence of Ebola in Uganda. At the 26 August check, the page was marked “Still in force: 26 August 2026” and its substantive advice remained unchanged. It recommends travel to the border areas of Uganda with the DRC only in absolutely essential cases and notes the closure of the Ugandan-Congolese border to normal movement of people. (in Czech)
Czech Ministry of Foreign Affairs (MFA): Congo (Kinshasa) – travel warning
At the 26 August check, this Czech travel warning for the DRC was marked “Still in force: 26 August 2026” and its substantive advice remained unchanged. In connection with Ebola it notes the occurrence in the DRC and the risk areas including the provinces of Ituri, North Kivu and South Kivu; it is best presented alongside the Ugandan advisory. (in Czech)
SZÚ: The Ebola epidemic in the DRC and Uganda, update of 3 June 2026
The official Czech overview of the current outbreak, the PHEIC and the risk assessment according to ECDC. Numerically it gives the older DRC status of 321 confirmed cases, 48 deaths and 116 suspected cases, so we do not use it as the main numerical figure for this version. (in Czech)
Czech Ministry of Health (MZd ČR): precautionary admission of a US citizen
The official Czech statement on the transport of the US physician, the isolation regime, the non-testing of asymptomatic people and the risk assessment for the public. (in Czech)
iROZHLAS / ČTK: Czech soldier in Těchonín
A relevant Czech media source of 2 June: the soldier returned on 22 May from a UN mission in the DRC, was precautionarily placed in the Těchonín Centre for Biological Protection, without symptoms and without confirmed direct contact with an infected person. (in Czech)
Czech MoD/VZÚ: Department of Biological Protection Těchonín
The official description of the military facility for biological protection, quarantine, decontamination and isolation of people with suspected highly dangerous infection. (in Czech)
Charité: the Berlin patient
The official German source on the confirmed-infected US physician treated at the Berlin Charité. A report of 6 June states that the patient was discharged in good health after isolation was lifted; his wife and four children were symptom-free throughout and without evidence of Bundibugyo virus. This case must be distinguished from the Czech precautionary isolations.
dpa / Süddeutsche Zeitung: discharge from the Charité
A German agency report of 6 June states that the patient was discharged in good health after more than two weeks of treatment. It complements the official Charité report.
Zdravotnický deník / ČTK: the Berlin patient
A Czech agency summary of the condition of the confirmed-infected US physician at the Berlin Charité; useful for correcting the inaccurate formulation that “patients transported to Germany are without symptoms”. (in Czech)
virological.org: initial genomes
Preliminary expert sharing of genomes from the current outbreak. Successive updates published the first three nearly complete genomes and then further sequences from the DRC, Uganda and from the patient treated in Germany. Counts in specific trees should be read according to the given update and not confused with the total number of records in Pathoplexus.
virological.org: molecular evolutionary analysis
A preliminary re-analysis published on 4 June with 10 sequences linked to the current outbreak and available as of 28 May. The authors estimate the common ancestor of the sampled viruses to early to mid-March 2026 and report high uncertainty due to the small number of sequences, the short time window and possible sampling bias.
virological.org: genomic epidemiology, 9 July 2026
The initial dataset of the new INRB-led analysis includes 139 DRC genomes sampled from 2 May to 23 June across 16 health zones: 138 from Ituri and one from North Kivu. After quality control, individual phylogenetic analyses use smaller subsets. Its common-ancestor estimate, doubling time of 11.7 days (95% HPD 6.8–17.5) and possible slowing signal are uncertain model-based results, not direct epidemiological counts.
Nature Medicine: Uganda index case, 11 June 2026
A short scientific communication published on 11 June, accepted on 9 June. It describes an older event: the Ugandan index case was admitted in Kampala on 11 May and died on 14 May. A post-mortem sample was positive for orthoebolavirus RNA and RT-qPCR confirmed BDBV; sequencing achieved 99% genome coverage at a depth of at least 100×. Nature notes that this is a non-final, unedited version of the manuscript, so we read it cautiously as a source of clinical and sequencing detail, not as a current case count.
Nature News Q&A: Inside the high-stakes race to develop an Ebola vaccine, 28 July 2026
The interview with trial lead Teresa Lambe confirms the previously reported Phase I start, approximately 50 participants aged 18–55, and assessment of safety and immune response. It is not a results paper. Trial parameters are checked against the University of Oxford and ISRCTN72157798; further studies in Uganda remain conditional on Phase I results and regulatory approval.
The Lancet Infectious Diseases, 25 June 2026
The article “Size of the 2026 Ebola outbreak and risk of cross-border spillover from Bundibugyo virus in Ituri Province, DR Congo, and its implications for preparedness” is a modelling study published online on 25 June. We use it only for interpreting cross-border spillover risk and preparedness; the model was calibrated to the status as of 8 June and does not replace current WHO/INSP counts.
Zhang et al., PNAS 2026: multivalent mRNA vaccine platform
A preclinical study published in PNAS on 26 May 2026, electronically on 18 May. The candidate [GPs+NP]@LNP encodes the glycoproteins of Ebola, Bundibugyo and Sudan viruses and the nucleoprotein of Ebola virus; the authors describe protection in experimental animal models. PubMed lists PMID 42150061. For the site this source is relevant only as a research direction for future broad-spectrum vaccines, not as an available vaccine for the current outbreak.
Nature Biotechnology: Broad-spectrum Ebola vaccine, 16 June 2026
A short expert report highlighting the work in PNAS. It is a secondary comment on the significance of the study, not a primary source for claims about efficacy or clinical availability.
Pathoplexus: Ebola-BDBV
A public sequence database for Bundibugyo virus. In the 26 August check, LAPIS aggregation showed 677 versioned database entries for outbreak Bdbv-2026: 655 from the DRC, 20 from Uganda and 2 from Germany, unchanged from the previous published version. Database entries are not clinical cases; their count is not the number of genomes in one analysis or evidence of a mutation changing viral properties.
iROZHLAS: questions and answers
Czech public context, an explanation of the risk and advice for travellers after returning from risk areas. (in Czech)
Zdravotnický deník: statement by the public health service
A Czech assessment of the importation risk and practical advice to monitor one's health status after returning. (in Czech)
AFP Fact Check: unproven treatment claims
An analysis of false claims about simple treatments for RNA viruses including Ebola; suitable for the misinformation page.
PolitiFact: Ebola outbreak and misinformation
A factual analysis of the most common misleading claims around the current outbreak.